/Investor DB

Astellas Venture Management LLC — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

Casma Therapeuticscasmatx.comin𝕏Series C · Nov 2022 · $46M✓ verified

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.

BiotechDeep TechHealthtechBoston, US

Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in

Co-investorsThird Rock VenturesEisai Innovation, Inc.Ono Venture Investment, Inc.The Column Group

Carbon Biosciences, Inc.carbonbio.comJan 2022

The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.

ConsumerGamingHealthtechBoston, US

Robert Kotin(Executive Officer, Director)Chen Schor(Director)Robert Hadfield(Executive Officer)John Lawrence(Executive Officer)

BoardGeeta Vemuri(Director)inDerek Yoon(Director)in

Co-investorsDC Investment PartnersSolasta VenturesUTokyo Innovation Platform Co. Ltd.Agent CapitalLongwood Fund

DEM BioPharmadembiopharma.comSeries A · Jun 2022 · $70M

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

Nenad Grmusa(Chief Executive Officer)inJohn McCabe(Chief Financial and Operating Officer)in

Co-investorsAlta PartnersDC Investment PartnersLongwood FundPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more

Ornaornatx.cominAug 2022

Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Daniel Anderson(Director)inThomas M. Barnes(Executive Officer, Director)Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)

Co-investorsMPM BioImpactTaiho Ventures, LLC

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.